DK1097937T3 - N-acylderivater af LL-E33288-antitumor-antibiotika - Google Patents

N-acylderivater af LL-E33288-antitumor-antibiotika

Info

Publication number
DK1097937T3
DK1097937T3 DK00128100T DK00128100T DK1097937T3 DK 1097937 T3 DK1097937 T3 DK 1097937T3 DK 00128100 T DK00128100 T DK 00128100T DK 00128100 T DK00128100 T DK 00128100T DK 1097937 T3 DK1097937 T3 DK 1097937T3
Authority
DK
Denmark
Prior art keywords
acyl derivatives
antitumor antibiotics
acyl
antitumor
antibiotics
Prior art date
Application number
DK00128100T
Other languages
Danish (da)
English (en)
Inventor
May Dean-Ming Lee
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Application granted granted Critical
Publication of DK1097937T3 publication Critical patent/DK1097937T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/44—Preparation of O-glycosides, e.g. glucosides
    • C12P19/60—Preparation of O-glycosides, e.g. glucosides having an oxygen of the saccharide radical directly bound to a non-saccharide heterocyclic ring or a condensed ring system containing a non-saccharide heterocyclic ring, e.g. coumermycin, novobiocin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/29—Micromonospora

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK00128100T 1989-04-14 1990-04-06 N-acylderivater af LL-E33288-antitumor-antibiotika DK1097937T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/338,928 US5079233A (en) 1987-01-30 1989-04-14 N-acyl derivatives of the LL-E33288 antitumor antibiotics, composition and methods for using the same

Publications (1)

Publication Number Publication Date
DK1097937T3 true DK1097937T3 (da) 2005-09-19

Family

ID=23326735

Family Applications (2)

Application Number Title Priority Date Filing Date
DK00128100T DK1097937T3 (da) 1989-04-14 1990-04-06 N-acylderivater af LL-E33288-antitumor-antibiotika
DK90106601T DK0392376T3 (da) 1989-04-14 1990-04-06 N-acylderivater af LL-E33288-antitumor-antibiotika

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK90106601T DK0392376T3 (da) 1989-04-14 1990-04-06 N-acylderivater af LL-E33288-antitumor-antibiotika

Country Status (22)

Country Link
US (1) US5079233A (de)
EP (2) EP1097937B1 (de)
JP (1) JP3083309B2 (de)
KR (1) KR0149493B1 (de)
CN (1) CN1027267C (de)
AT (2) ATE297405T1 (de)
AU (1) AU627863B2 (de)
CA (1) CA2014472C (de)
CZ (2) CZ297668B6 (de)
DE (2) DE69033839T2 (de)
DK (2) DK1097937T3 (de)
ES (2) ES2240000T3 (de)
FI (1) FI97889C (de)
IE (1) IE20011013A1 (de)
IL (1) IL93732A (de)
NO (1) NO172938C (de)
NZ (1) NZ233149A (de)
PH (1) PH27361A (de)
PT (1) PT93715B (de)
SG (1) SG47857A1 (de)
SK (1) SK188390A3 (de)
ZA (1) ZA902839B (de)

Families Citing this family (126)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5712374A (en) * 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
JPH11513690A (ja) * 1995-10-20 1999-11-24 ユニバーシティ・オブ・ユタ・リサーチ・ファウンデイション 海生ホヤ ポリシンクラトン・リソストロツムからのエンジイン抗腫瘍抗生物質ナメナマイシン
ATE481487T1 (de) 1998-11-27 2010-10-15 Ucb Sa Zusammensetzungen und verfahren zur erhöhung der knochenmineralisierung
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
US20060228364A1 (en) * 1999-12-24 2006-10-12 Genentech, Inc. Serum albumin binding peptides for tumor targeting
US20040001827A1 (en) * 2002-06-28 2004-01-01 Dennis Mark S. Serum albumin binding peptides for tumor targeting
EP1240337B1 (de) * 1999-12-24 2006-08-23 Genentech, Inc. Verfahren und verbindungen zur verlängerung der halbwertzeiten bei der ausscheidung von biowirksamen verbindungen
US20050287153A1 (en) * 2002-06-28 2005-12-29 Genentech, Inc. Serum albumin binding peptides for tumor targeting
US20040023910A1 (en) * 2001-09-28 2004-02-05 Zhiming Zhang Use of cyr61 in the treatment and diagnosis of human uterine leiomyomas
US20110045005A1 (en) 2001-10-19 2011-02-24 Craig Crowley Compositions and methods for the treatment of tumor of hematopoietic origin
SG187991A1 (en) 2002-05-02 2013-03-28 Wyeth Corp Calicheamicin derivative-carrier conjugates
CA2529623A1 (en) 2003-06-16 2005-02-17 Celltech R & D, Inc. Antibodies specific for sclerostin and methods for increasing bone mineralization
AU2004261980A1 (en) * 2003-08-01 2005-02-10 Genentech, Inc. Antibody CDR polypeptide sequences with restricted diversity
US20050282168A1 (en) * 2003-09-29 2005-12-22 Wyeth Cell surface molecules as markers and therapeutic agents against kidney cancers
EP2478912B1 (de) 2003-11-06 2016-08-31 Seattle Genetics, Inc. Konjugate von Auristatin mit gegen HER2- oder CD22-gerichtete Antikörper und deren therapeutische Verwendung
PT1718677E (pt) 2003-12-19 2012-07-18 Genentech Inc Fragmentos de anticorpo monovalentes úteis como agentes terapêuticos
AR048098A1 (es) * 2004-03-15 2006-03-29 Wyeth Corp Conjugados de caliqueamicina
NZ579482A (en) 2004-06-01 2011-02-25 Genentech Inc Antibody drug conjugates and methods
US20060222850A1 (en) * 2005-04-01 2006-10-05 The University Of Chicago Synthesis of a self assembled hybrid of ultrananocrystalline diamond and carbon nanotubes
WO2006026759A2 (en) * 2004-09-03 2006-03-09 Genentech, Inc. Humanized anti-beta7 antagonists and uses therefor
SV2007002227A (es) * 2004-09-10 2007-03-20 Wyeth Corp Anticuerpos anti-5t4 humanizados y conjugados anticuerpo anti-5t4/calicheamicina ref. 040000-0317637
DK1791565T3 (en) 2004-09-23 2016-08-01 Genentech Inc Cysteingensplejsede antibodies and conjugates
MX2007003907A (es) * 2004-10-05 2007-05-21 Genentech Inc Agentes terapeuticos con toxicidad reducida.
JP4993645B2 (ja) 2004-12-01 2012-08-08 ジェネンテック， インコーポレイテッド 抗体薬剤結合体および方法
US20070003559A1 (en) * 2005-07-01 2007-01-04 Wyeth Methods of determining pharmacokinetics of targeted therapies
ES2577292T3 (es) 2005-11-07 2016-07-14 Genentech, Inc. Polipéptidos de unión con secuencias hipervariables de VH/VL diversificadas y consenso
EP1973951A2 (de) * 2005-12-02 2008-10-01 Genentech, Inc. Bindende polypeptide mit eingeschränkten diversitätssequenzen
CA2631327C (en) * 2005-12-02 2015-10-13 Genentech, Inc. Her2 binding polypeptides and uses thereof
EP1957097A1 (de) * 2005-12-06 2008-08-20 Wyeth a Corporation of the State of Delaware Interleukin-11-zusammensetzungen und anwendungsverfahren
CA2633887C (en) 2005-12-15 2015-12-22 Genentech, Inc. Methods and compositions for targeting polyubiquitin
BRPI0706840A2 (pt) 2006-01-05 2011-04-05 Genentech Inc anticorpos anti- ephb4 isolado polinucleotìdeo, vetor, célula hospedeira, método para produção de um anticorpo anti ephb4, método para produção de um imunoconjugado anti ephb4, método para a detecção de ephb4, método para diagnosticar um distúrbio composição, método para inibir a angiogênese, método para tratar um cáncer, tumor e/ou distúrbio da proliferação celular e uso de um anticorpo
TW200806685A (en) * 2006-02-21 2008-02-01 Wyeth Corp Processes for the convergent synthesis of calicheamicin derivatives
DK2368914T3 (en) 2006-03-10 2019-03-04 Wyeth Llc Anti-5T4 antibodies and uses thereof
AR059851A1 (es) 2006-03-16 2008-04-30 Genentech Inc Anticuerpos de la egfl7 y metodos de uso
EP2032606B1 (de) 2006-05-30 2013-11-27 Genentech, Inc. Antikörper und immunkonjugate sowie ihre verwendungen
BRPI0717638A2 (pt) 2006-10-27 2013-11-12 Genentech Inc Anticorpors e imunoconjugados e usos para os mesmos
MX2009008430A (es) 2007-02-09 2009-10-28 Genentech Inc Anticuerpos anti-robo4 y sus usos.
US7960139B2 (en) 2007-03-23 2011-06-14 Academia Sinica Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
KR101547705B1 (ko) 2007-05-22 2015-08-26 와이어쓰 엘엘씨 히드라지드의 개선된 제조 방법
PE20090309A1 (es) * 2007-06-04 2009-04-18 Wyeth Corp Conjugado portador-caliqueamicina y un metodo de deteccion de caliqueamicina
PE20090321A1 (es) 2007-06-04 2009-04-20 Genentech Inc Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica
TWI468417B (zh) 2007-11-30 2015-01-11 Genentech Inc 抗－ｖｅｇｆ抗體
BRPI0907046A2 (pt) 2008-01-18 2015-07-28 Medimmune Llc Anticorpo de cisteína engenheirada, ácido nucleico isolado, vetor, célula hospedeira, conjugado de anticorpo, composição farmacêutica, métodos de detecção de câncer, doenças ou distúrbios autoimunes, inflamatórios ou infecciosos em um indivíduo e de inibição de proliferação de uma célula alvo
SG10202112838YA (en) 2008-04-09 2021-12-30 Genentech Inc Novel compositions and methods for the treatment of immune related diseases
KR101361905B1 (ko) * 2008-05-16 2014-02-21 제넨테크, 인크. 베타7 인테그린 길항제를 이용한 위장관 염증 장애의 치료를 평가하기 위한 바이오마커의 용도
ES2442024T3 (es) 2008-07-15 2014-02-07 Academia Sinica Matrices de glucano sobre portaobjetos de vidrio revestidos con aluminio de tipo PTFE y métodos relacionados
MY152068A (en) 2009-03-20 2014-08-15 Genentech Inc Bispecific anti-her antibodies
MA33208B1 (fr) 2009-03-25 2012-04-02 Genentech Inc Anticorps anti-fgfr3 et procédés d'utilisation de ceux-ci
EP2711018A1 (de) 2009-06-22 2014-03-26 MedImmune, LLC Manipulierte Fc-Regionen für standortspezifische Konjugation
CA2772715C (en) 2009-09-02 2019-03-26 Genentech, Inc. Mutant smoothened and methods of using the same
MX2012002013A (es) 2009-10-19 2012-03-16 Genentech Inc Moduladores de activador del factor de crecimiento de hepatocitos.
RU2559533C2 (ru) 2009-10-22 2015-08-10 Дженентек, Инк. Антитела против гепсина и способы их применения
JP5819308B2 (ja) 2009-10-22 2015-11-24 ジェネンテック， インコーポレイテッド マクロファージ刺激タンパク質のヘプシン活性化を調節するための方法及び組成物
WO2011056502A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Bone morphogenetic protein receptor type ii compositions and methods of use
WO2011056497A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor type iib compositions and methods of use
WO2011056494A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
EP2496601B1 (de) 2009-11-05 2017-06-07 F. Hoffmann-La Roche AG Methoden und zusammensetzung zur sekretion heterologer polypeptide
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
US11377485B2 (en) 2009-12-02 2022-07-05 Academia Sinica Methods for modifying human antibodies by glycan engineering
WO2011071577A1 (en) 2009-12-11 2011-06-16 Genentech, Inc. Anti-vegf-c antibodies and methods using same
EP2516465B1 (de) 2009-12-23 2016-05-18 F.Hoffmann-La Roche Ag Anti-bv8 antikörper und deren verwendungen
KR101723615B1 (ko) 2010-01-12 2017-04-06 한상선 천연 한약재를 이용한 샴푸 조성물
CN102844045A (zh) 2010-02-08 2012-12-26 艾更斯司股份有限公司 结合于161p2f10b蛋白的抗体药物偶联物(adc)
US10338069B2 (en) 2010-04-12 2019-07-02 Academia Sinica Glycan arrays for high throughput screening of viruses
NZ701208A (en) 2010-06-03 2016-05-27 Genentech Inc Immuno-pet imaging of antibodies and immunoconjugates and uses thereof
MX347954B (es) 2010-09-29 2017-05-19 Agensys Inc Conjugados de anticuerpo farmaco (adc) que enlazan a proteinas 191p4d12.
DK2625197T3 (en) 2010-10-05 2016-10-03 Genentech Inc Smoothened MUTANT AND METHODS OF USING THE SAME
WO2012092539A2 (en) 2010-12-31 2012-07-05 Takeda Pharmaceutical Company Limited Antibodies to dll4 and uses thereof
US9540443B2 (en) 2011-01-26 2017-01-10 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies
MX2014004991A (es) 2011-10-28 2014-05-22 Genentech Inc Combinaciones terapeuticas y metodos para tratar el melanoma.
EP2589609A1 (de) 2011-11-03 2013-05-08 Pierre Fabre Medicament Antigenbindendes Protein und dessen Verwendung als Adressierungsprodukt bei der Behandlung von Krebs
CN102584915B (zh) * 2011-12-31 2014-07-23 沈阳药科大学 一种芳香酸类化合物及其用途
JP2015509091A (ja) 2012-01-09 2015-03-26 ザ スクリプス リサーチ インスティテュート ヒト化抗体
CA2863224A1 (en) 2012-01-09 2013-07-18 The Scripps Research Institute Ultralong complementarity determining regions and uses thereof
US10130714B2 (en) 2012-04-14 2018-11-20 Academia Sinica Enhanced anti-influenza agents conjugated with anti-inflammatory activity
HK1210192A1 (en) 2012-07-19 2016-04-15 Alethia Biotherapeutics Inc. Anti-siglec-15 antibodies
NZ630363A (en) 2012-07-25 2018-09-28 Celldex Therapeutics Inc Anti-kit antibodies and uses thereof
WO2014031498A1 (en) 2012-08-18 2014-02-27 Academia Sinica Cell-permeable probes for identification and imaging of sialidases
TWI606063B (zh) 2012-08-23 2017-11-21 艾澤西公司 結合至１５８ｐ１ｄ７蛋白之抗體藥物結合物（ａｄｃ）
PL2914630T3 (pl) 2012-11-05 2021-09-06 Pierre Fabre Médicament Nowe białka wiążące antygen i ich zastosowanie jako produktu ukierunkowanego do leczenia raka
EP3013365B1 (de) 2013-06-26 2019-06-05 Academia Sinica Rm2-antigene und verwendung davon
EP3013347B1 (de) 2013-06-27 2019-12-11 Academia Sinica Glykankonjugate und verwendung davon
CA2918370A1 (en) 2013-07-18 2015-01-22 Fabrus, Inc. Humanized antibodies with ultralong complementarity determining regions
WO2015017146A2 (en) 2013-07-18 2015-02-05 Fabrus, Inc. Antibodies with ultralong complementarity determining regions
WO2015017552A1 (en) 2013-08-01 2015-02-05 Agensys, Inc. Antibody drug conjugates (adc) that bind to cd37 proteins
JP6486368B2 (ja) 2013-09-06 2019-03-20 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ 改変されたグリコシル基を含む糖脂質を用いたヒトｉＮＫＴ細胞の活性化
JP2016540826A (ja) 2013-11-04 2016-12-28 ファイザー・インク 抗ｅｆｎａ４抗体−薬物コンジュゲート
AU2015206370A1 (en) 2014-01-16 2016-07-07 Academia Sinica Compositions and methods for treatment and detection of cancers
US10150818B2 (en) 2014-01-16 2018-12-11 Academia Sinica Compositions and methods for treatment and detection of cancers
US10562977B2 (en) 2014-01-29 2020-02-18 Shanghai Hengrui Pharmaceutical Co., Ltd. Ligand-cytotoxic drug conjugate, preparation method thereof, and uses thereof
ES2694857T3 (es) 2014-02-04 2018-12-27 Genentech, Inc. Smoothened mutante y métodos de uso de la misma
CN106415244B (zh) 2014-03-27 2020-04-24 中央研究院 反应性标记化合物及其用途
DK3134438T3 (da) 2014-04-25 2020-12-07 Pf Medicament IGF-1R-antistof og anvendelse heraf som adresseringsvehikel til behandling af cancer
RU2708075C2 (ru) 2014-04-30 2019-12-04 Пфайзер Инк. Конъюгаты анти-ртк7 антитело-лекарственное средство
US10118969B2 (en) 2014-05-27 2018-11-06 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
CN106661099A (zh) 2014-05-27 2017-05-10 中央研究院 抗her2醣抗体及其用途
JP7093612B2 (ja) 2014-05-27 2022-06-30 アカデミア シニカ Ｂａｃｔｅｒｏｉｄｅｓ由来のフコシダーゼおよびそれを使用する方法
CA2950415A1 (en) 2014-05-27 2015-12-03 Academia Sinica Anti-cd20 glycoantibodies and uses thereof
WO2015184001A1 (en) 2014-05-28 2015-12-03 Academia Sinica Anti-tnf-alpha glycoantibodies and uses thereof
WO2016034968A1 (en) 2014-09-02 2016-03-10 Pfizer Inc. Therapeutic antibody
TWI745275B (zh) 2014-09-08 2021-11-11 中央研究院 使用醣脂激活人類ｉＮＫＴ細胞
CA2961439A1 (en) 2014-11-05 2016-05-12 Genentech, Inc. Anti-fgfr2/3 antibodies and methods using same
US9975965B2 (en) 2015-01-16 2018-05-22 Academia Sinica Compositions and methods for treatment and detection of cancers
US10495645B2 (en) 2015-01-16 2019-12-03 Academia Sinica Cancer markers and methods of use thereof
JP6779887B2 (ja) 2015-01-24 2020-11-04 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ 新規なグリカンコンジュゲートおよびその使用方法
AU2016209056B2 (en) 2015-01-24 2021-01-28 Academia Sinica Cancer markers and methods of use thereof
EP3253784B1 (de) 2015-02-04 2020-05-06 Genentech, Inc. Smoothened-mutant und verfahren zur verwendung davon
EP3365025B1 (de) 2015-10-20 2020-07-15 Genentech, Inc. Calicheamicin-antikörper-arzneimittelkonjugate und verfahren zur verwendung
SI3383920T1 (sl) 2015-11-30 2024-06-28 The Regents Of The University Of California Dostava tumorsko specifičnega koristnega tovora in imunska aktivacija z uporabo humanega protitelesa, ki cilja visoko specifičen površinski antigen tumorskih celic
EP3411396A1 (de) 2016-02-04 2018-12-12 Curis, Inc. Smoothened-mutant und verfahren zur verwendung davon
WO2017153432A1 (en) 2016-03-07 2017-09-14 Pierre Fabre Medicament A new universal method to capture and analyze adcs for characterization of drug distribution and the drug-to-antibody ratio in biological samples
EP3426693A4 (de) 2016-03-08 2019-11-13 Academia Sinica Verfahren zur modularen synthese von n-glykanen und anordnungen davon
BR112018070948A2 (pt) 2016-04-13 2019-01-29 Orimabs Ltd. anticorpos anti-psma e utilização dos mesmos
JP2019524706A (ja) 2016-07-08 2019-09-05 ジェネンテック， インコーポレイテッド Ｍｕｃ１６陽性癌治療の応答性を評価するためのヒト精巣上体タンパク質４（ｈｅ４）の使用
CA3034057A1 (en) 2016-08-22 2018-03-01 CHO Pharma Inc. Antibodies, binding fragments, and methods of use
WO2019018647A1 (en) 2017-07-20 2019-01-24 Pfizer Inc. ANTI-GD3 ANTIBODIES AND CONJUGATES ANTIBODY-MEDICATION
EP3720504A1 (de) 2017-12-06 2020-10-14 Synaffix B.V. Enediynkonjugate
CA3107383A1 (en) 2018-07-23 2020-01-30 Magenta Therapeutics, Inc. Use of anti-cd5 antibody drug conjugate (adc) in allogeneic cell therapy
WO2020063676A1 (zh) 2018-09-26 2020-04-02 江苏恒瑞医药股份有限公司 依喜替康类似物的配体-药物偶联物及其制备方法和应用
WO2021010326A1 (ja) 2019-07-12 2021-01-21 中外製薬株式会社 抗変異型ｆｇｆｒ３抗体およびその使用
US20220306736A1 (en) 2019-09-04 2022-09-29 Y-Biologics Inc. Anti-vsig4 antibody or antigen binding fragment and uses thereof
JP7821733B2 (ja) 2020-01-22 2026-02-27 上海森輝医薬有限公司 エリブリン誘導体の薬物複合体、その調製方法及びその医薬的応用
CN115103858B (zh) 2020-03-25 2025-07-15 江苏恒瑞医药股份有限公司 一种抗体药物偶联物的制备方法
BR112022019073A2 (pt) 2020-03-25 2022-11-08 Jiangsu Hengrui Pharmaceuticals Co Ltd Composição farmacêutica que compreende conjugado anticorpo-fármaco e uso da mesma
US20240158503A1 (en) 2021-03-03 2024-05-16 Pierre Fabre Medicament Anti-vsig4 antibody or antigen binding fragment and uses thereof
US20240209094A1 (en) 2021-04-30 2024-06-27 Pierre Fabre Medicament New stable anti-vista antibody

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5644076B2 (de) * 1973-07-12 1981-10-16
EP0276485B1 (de) * 1987-01-30 2002-06-12 American Cyanamid Company Dihydroderivate der Antibiotika vom Typ LL-E33288
US4837206A (en) * 1987-04-29 1989-06-06 Bristol-Myers Company Esperamicin derivatives
ATE112172T1 (de) * 1987-10-30 1994-10-15 American Cyanamid Co Targetformer von antitumor-methyltrithioagenzien.
IL93733A (en) * 1989-04-14 1996-01-19 American Cyanamid Co Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group and targeted forms thereof

Also Published As

Publication number Publication date
AU627863B2 (en) 1992-09-03
ES2162783T3 (es) 2002-01-16
JPH032192A (ja) 1991-01-08
IE20011013A1 (en) 2002-12-30
NO172938C (no) 1993-12-29
DE69034194D1 (de) 2005-07-14
PT93715B (pt) 1996-08-30
FI901865A0 (fi) 1990-05-12
EP0392376A3 (de) 1991-08-14
HK1035540A1 (en) 2001-11-30
NO172938B (no) 1993-06-21
ATE207926T1 (de) 2001-11-15
CZ284618B6 (cs) 1999-01-13
CA2014472C (en) 2000-03-28
ES2240000T3 (es) 2005-10-16
DE69033839T2 (de) 2002-06-06
CA2014472A1 (en) 1990-10-14
EP1097937B1 (de) 2005-06-08
CZ297668B6 (cs) 2007-02-28
PH27361A (en) 1993-06-21
NO901654D0 (no) 1990-04-11
SK281179B6 (sk) 2000-12-11
KR900016242A (ko) 1990-11-13
CN1027267C (zh) 1995-01-04
JP3083309B2 (ja) 2000-09-04
CN1048390A (zh) 1991-01-09
FI97889C (fi) 1997-03-10
NO901654L (no) 1990-10-15
IL93732A0 (en) 1990-12-23
CZ53598A3 (cs) 1998-09-16
ZA902839B (en) 1991-12-24
DK0392376T3 (da) 2001-12-03
FI97889B (fi) 1996-11-29
IL93732A (en) 1994-11-28
HK1011368A1 (en) 1999-07-09
PT93715A (pt) 1990-11-20
CZ188390A3 (cs) 1998-10-14
DE69033839D1 (de) 2001-12-06
ATE297405T1 (de) 2005-06-15
SG47857A1 (en) 1998-04-17
EP1097937A1 (de) 2001-05-09
EP0392376B1 (de) 2001-10-31
SK188390A3 (en) 2000-12-11
US5079233A (en) 1992-01-07
DE69034194T2 (de) 2005-11-03
AU5324890A (en) 1990-10-18
EP0392376A2 (de) 1990-10-17
KR0149493B1 (ko) 1998-08-17
NZ233149A (en) 1996-02-27

Similar Documents

Publication Publication Date Title
DK1097937T3 (da) N-acylderivater af LL-E33288-antitumor-antibiotika
NO932869D0 (no) 7-(substituerte)-9-((substituerte glycyl)amido)-6-demetyl-6-deoksytetracykliner
FI933564A0 (fi) Nya 7-(substituerad)-8-(substituerad)-9-((substituerad)glycyl)amido)-6-demetyl-6-deoxitetracykliner
PT582810E (pt) Novas 7-(substituidas)-8-(substituidas)-9-(substituidas)-6-desmetil-6-desoxitetraciclinas como agentes antibioticos
FI904851A0 (fi) Radiomaerkta antikoagulantpeptider.
DE69123312D1 (de) Kalziumphosphat Glaskeramik
FI894671A0 (fi) Reglerbar faestanordning.
ES2129397T3 (es) Derivados heteroaroilo de antibioticos beta-lactamas monociclicos.
MX9205003A (es) Derivados novedosos de benzopirano.
MX9102079A (es) Plemezcla de semduramicina
FI931018A7 (fi) 2-deoksistreptamiini-tyyppisen antibiootin käyttö
ATE139519T1 (de) Stabilisiertes 141b
FR2597105B1 (fr) Derives antibiotiques de la famille des 20-0-acyl-19,20-enolmacrolides
MX9202911A (es) Compuestos pseudoagliconas de los antibioticos del complejo ll-e33288.
FI923310A7 (fi) Pradimisiiniantibioottien tuotanto
MX9202870A (es) Conjugados acarreador-farmaco de la familia de los agentes antitumorales y antibioticos del metiltritio.
RO97339A2 (ro) Sursa trifazata de foarte joasa frecventa
ES1019673Y (es) Prenda de vestir interior de efectos luminosos.
KR920013544U (ko) 스위치의 고정장치
BR6902067U (pt) Aperfeicoamento de dispositivo de contorneamento
MX9206709A (es) Derivados de fenol
ES1014485Y (es) Soporte de canalon o palomilla.
BR6900692U (pt) Volatilizador de ambientes
ES288494Y (es) Dispositivo luminoso de colores en movimiento
BR6802719U (pt) Disposicao construtiva de quadros